Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Publications indexed to the term Piperidines

FacultyTitle
1HJ-4, a novel piperine derivative, inhibits tumor growth and angiogenesis via p53 activation and oncogenic pathway inhibition in colorectal cancer models. (Zhang L, Liu S, Wang D, Zhang X, Hu Z, Zou X, Li X, Wang X, Xu D, Liu W, Liu B) Sci Rep 2025 Sep 29;15(1):33541    
1Dual acting inhibitor of soluble epoxide hydrolase and Cyclooxygenase-2, attenuates glomerular injury in renal hypoplasia mice. (Hye Khan MA, Goorani S, Atamanchuk A, Jankiewicz W, Yeboah MM, Barnett SD, Falck JR, Hwang SH, Barnych B, Hammock BD, El-Meanawy A, Imig JD) Eur J Pharmacol 2025 Nov 05;1006:178132    
1Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson's disease. (Ayerra L, Abellanas MA, Vidaurre C, Basurco L, Tavira A, Luquin E, Clavero P, Mengual E, Collantes M, Peñuelas I, de Martin-Esteban SR, Grether U, Hillard CJ, Romero J, Hervás-Stubbs S, Aymerich MS) Brain Behav Immun 2025 Aug;128:600-611       1 Citation
1Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. (Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis L, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF) Blood 2025 Jul 24;146(4):422-436       2 Citations
2A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings. (Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC Jr, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B) Front Immunol 2024;15:1369619       2 Citations
1A novel piperine derivative HJJ_3_5 inhibits colorectal cancer progression by modulating EMT signaling pathways. (Cheng W, Liu S, He J, Li H, Liu X, Hu Z, Wang X, Wu Z, Xu G, Liu W, Liu B) Biochem Biophys Res Commun 2025 Feb 16;749:151323       5 Citations
3Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis. (Pidala J, Kim J, Kalos D, Cutler C, DeFilipp Z, Flowers MED, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko C, Ponce D, Sung A, Tang H, Farhadfar N, Nemecek E, Pusic I, Qayed M, Rangarajan H, Hogan W, Etra A, Jaglowski S) Blood Adv 2025 Mar 11;9(5):1040-1048       6 Citations
1Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. (Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators) Lancet Neurol 2024 Nov;23(11):1119-1132       40 Citations
1Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. (Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A) Ann Oncol 2024 Nov;35(11):981-992       69 Citations
1Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. (Mutch D, Voulgari A, Chen XM, Bradley WH, Oaknin A, Perez Fidalgo JA, Montosa FG, Herraez AC, Holloway RW, Powell MA, Nowicka M, Schaefer G, Merchant M, Yan Y) Cancer 2024 Jun 01;130(11):1940-1951       4 Citations
1Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. (Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett NL) Blood Adv 2024 Feb 13;8(3):549-552    
1Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. (Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, Subbiah V) ESMO Open 2023 Dec;8(6):101609       3 Citations
1A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. (Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, Calkins MM, Bautista-Carro MA, Arsenault E, Telfer A, Taghavi-Abkuh FF, Malcolm NJ, El Sayegh F, Abizaid A, Schmid Y, Morton K, Halberstadt AL, Aguilar-Valles A, McCorvy JD) Cell Rep 2023 Mar 28;42(3):112203       79 Citations
1Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. (Sigmund AM, Huang Y, Ruppert AS, Maddocks K, Rogers KA, Jaglowski S, Bhat SA, Kittai AS, Grever MR, Byrd JC, Woyach JA) Leukemia 2022 Aug;36(8):2129-2131       3 Citations
1Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. (Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA) Clin Cancer Res 2022 Aug 02;28(15):3242-3247       23 Citations
1Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. (O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A) Gynecol Oncol 2022 Jul;166(1):36-43       24 Citations
1Development of novel phenoxyalkylpiperidines as high-affinity Sigma-1 (σ1) receptor ligands with potent anti-amnesic effect. (Abatematteo FS, Mosier PD, Niso M, Brunetti L, Berardi F, Loiodice F, Contino M, Delprat B, Maurice T, Laghezza A, Abate C) Eur J Med Chem 2022 Jan 15;228:114038       3 Citations
1Regulation of learned fear expression through the MgN-amygdala pathway. (Ferrara NC, Trask S, Pullins SE, Helmstetter FJ) Neurobiol Learn Mem 2021 Nov;185:107526       6 Citations
1Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. (Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, Jaglowski S, Pidala J, Cutler C) Transplant Cell Ther 2021 Dec;27(12):990.e1-990.e7       25 Citations
1Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. (Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, Rogers KA, Bhat S, Kittai AS, Grever M, Lapalombella R, Abruzzo LV, Heerema NA, Byrd JC, Hertlein EK, Woyach JA) Leukemia 2021 Nov;35(11):3287-3290       1 Citation
1Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. (Fenster M, Alayo QA, Khatiwada A, Wang W, Dimopoulos C, Gutierrez A, Ciorba MA, Christophi GP, Hirten RP, Ha C, Beniwal-Patel P, Cohen BL, Syal G, Yarur A, Patel A, Colombel JF, Pekow J, Ungaro RC, Rubin DT, Deepak P) Clin Gastroenterol Hepatol 2021 Oct;19(10):2207-2209.e3       28 Citations
1Enhanced T-type calcium channel 3.2 activity in sensory neurons contributes to neuropathic-like pain of monosodium iodoacetate-induced knee osteoarthritis. (Shin SM, Cai Y, Itson-Zoske B, Qiu C, Hao X, Xiang H, Hogan QH, Yu H) Mol Pain 2020;16:1744806920963807       23 Citations
2Role of opioid signaling in kidney damage during the development of salt-induced hypertension. (Golosova D, Palygin O, Bohovyk R, Klemens CA, Levchenko V, Spires DR, Isaeva E, El-Meanawy A, Staruschenko A) Life Sci Alliance 2020 Dec;3(12)       24 Citations
1Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. (Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P, GIMEMA, European Research Initiative (ERIC) on CLL, US study group) Cancer Med 2020 Nov;9(22):8468-8479       13 Citations
1Antidepressant-like effects of URB597 and JZL184 in male and female rats exposed to early life stress. (Alteba S, Mizrachi Zer-Aviv T, Tenenhaus A, Ben David G, Adelman J, Hillard CJ, Doron R, Akirav I) Eur Neuropsychopharmacol 2020 Oct;39:70-86       29 Citations
11-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats. (Bukhari IA, Alorainey BI, Al-Motrefi AA, Mahmoud A, Campbell WB, Hammock BD) Eur Rev Med Pharmacol Sci 2020 Aug;24(15):8143-8150       5 Citations
1Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. (Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A) Clin Gastroenterol Hepatol 2021 Aug;19(8):1592-1601.e3       87 Citations
2Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. (Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M) Br J Haematol 2020 Jul;190(2):e98-e101       11 Citations
1CCL2 mediates early renal leukocyte infiltration during salt-sensitive hypertension. (Alsheikh AJ, Dasinger JH, Abais-Battad JM, Fehrenbach DJ, Yang C, Cowley AW Jr, Mattson DL) Am J Physiol Renal Physiol 2020 Apr 01;318(4):F982-F993       24 Citations
1Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. (Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2020 Jun;82(6):1445-1486       271 Citations
1First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. (Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS) Clin Cancer Res 2020 Mar 15;26(6):1237-1246       83 Citations
4Response to: "Alvimopan and outcome after colectomy?". (Hu KY, Peterson CY, Ludwig KA, Ridolfi TJ) Surgery 2020 Mar;167(3):677    
1High-affinity sigma-1 (σ1) receptor ligands based on the σ1 antagonist PB212. (Niso M, Mosier PD, Marottoli R, Ferorelli S, Cassano G, Gasparre G, Leopoldo M, Berardi F, Abate C) Future Med Chem 2019 Oct;11(19):2547-2562       6 Citations
1Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. (Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, Carrasco R, Rosenzweig S, Goldbach-Mansky R, Rider LG) Brain 2019 Nov 01;142(11):e59       72 Citations
1Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators) N Engl J Med 2019 Dec 19;381(25):2391-2402       1759 Citations
6Alvimopan is associated with decreased length of stay for both open and laparoscopic segmental colectomy. (Henning RE, Hu KY, Rein LE, Szabo A, Peterson CY, Ludwig KA, Ridolfi TJ) Surgery 2019 Oct;166(4):483-488       9 Citations
1Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. (Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S) Biol Blood Marrow Transplant 2019 Oct;25(10):2002-2007       93 Citations
1Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2019 Apr;80(4):1029-1072       764 Citations
1Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). (Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P) Leuk Lymphoma 2019 Jul;60(7):1650-1655       36 Citations
1Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? (Abid MB, Stromich J, Gundacker ND) Cancer Biol Ther 2019;20(2):138-140       8 Citations
1Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. (Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C) Am J Hematol 2018 Nov;93(11):1394-1401       60 Citations
1How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. (Jaglowski SM, Blazar BR) Blood Adv 2018 Aug 14;2(15):2012-2019       81 Citations
1Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD. (Fidelman S, Mizrachi Zer-Aviv T, Lange R, Hillard CJ, Akirav I) Eur Neuropsychopharmacol 2018 May;28(5):630-642       59 Citations
1Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. (O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE) JAMA Oncol 2018 May 01;4(5):712-716       20 Citations
3Stress Promotes Drug Seeking Through Glucocorticoid-Dependent Endocannabinoid Mobilization in the Prelimbic Cortex. (McReynolds JR, Doncheck EM, Li Y, Vranjkovic O, Graf EN, Ogasawara D, Cravatt BF, Baker DA, Liu QS, Hillard CJ, Mantsch JR) Biol Psychiatry 2018 Jul 15;84(2):85-94       48 Citations
1Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). (Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P) J Hematol Oncol 2017 Nov 02;10(1):171       46 Citations
1Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. (Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA) Blood 2018 Jan 11;131(2):182-190       130 Citations
1Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. (Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S) Blood 2017 Nov 23;130(21):2243-2250       415 Citations
417β-Estradiol Potentiates the Reinstatement of Cocaine Seeking in Female Rats: Role of the Prelimbic Prefrontal Cortex and Cannabinoid Type-1 Receptors. (Doncheck EM, Urbanik LA, DeBaker MC, Barron LM, Liddiard GT, Tuscher JJ, Frick KM, Hillard CJ, Mantsch JR) Neuropsychopharmacology 2018 Mar;43(4):781-790       36 Citations
3A Subregion of the Parabrachial Nucleus Partially Mediates Respiratory Rate Depression from Intravenous Remifentanil in Young and Adult Rabbits. (Miller JR, Zuperku EJ, Stuth EAE, Banerjee A, Hopp FA, Stucke AG) Anesthesiology 2017 Sep;127(3):502-514       41 Citations
1Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. (Starenki D, Hong SK, Wu PK, Park JI) Cancer Biol Ther 2017 Jul 03;18(7):473-483       18 Citations
1BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC) J Clin Oncol 2017 May 01;35(13):1437-1443       420 Citations
1Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. (Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL) Ann Pharmacother 2017 Jun;51(6):479-487       35 Citations
1The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. (Guinn D, Lehman A, Fabian C, Yu L, Maddocks K, Andritsos LA, Jones JA, Flynn JM, Jaglowski SM, Woyach JA, Byrd JC, Johnson AJ) Cancer Med 2017 Apr;6(4):778-787       15 Citations
1Cardiomyocyte Differentiation Promotes Cell Survival During Nicotinamide Phosphoribosyltransferase Inhibition Through Increased Maintenance of Cellular Energy Stores. (Kropp EM, Broniowska KA, Waas M, Nycz A, Corbett JA, Gundry RL) Stem Cells Transl Med 2017 Apr;6(4):1191-1201       2 Citations
3Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Dec;35(4):528-535       61 Citations
1Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. (Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB) Blood 2016 Dec 22;128(25):2899-2908       66 Citations
1Coordinated regulation of endocannabinoid-mediated retrograde synaptic suppression in the cerebellum by neuronal and astrocytic monoacylglycerol lipase. (Liu X, Chen Y, Vickstrom CR, Li Y, Viader A, Cravatt BF, Liu QS) Sci Rep 2016 Oct 24;6:35829       19 Citations
1Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66       7 Citations
1Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. (Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K) J Dermatolog Treat 2017 Feb;28(1):3-7       13 Citations
1Responses to drugs of abuse and non-drug rewards in leptin deficient ob/ob mice. (Muelbl MJ, Nawarawong NN, Clancy PT, Nettesheim CE, Lim YW, Olsen CM) Psychopharmacology (Berl) 2016 Jul;233(14):2799-811       22 Citations
1Ibrutinib for treatment of chronic lymphocytic leukemia. (Vela CM, McBride A, Jaglowski SM, Andritsos LA) Am J Health Syst Pharm 2016 Mar 15;73(6):367-75       13 Citations
1In reply: Sevoflurane or desflurane: Which one is more expensive? Limiting the accessibility of cost-prohibitive drugs: The story is incomplete. (Tabing AK, Ehrenfeld JM, Wanderer JP) Can J Anaesth 2016 Mar;63(3):361       1 Citation
2CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats. (McReynolds JR, Doncheck EM, Vranjkovic O, Ganzman GS, Baker DA, Hillard CJ, Mantsch JR) Psychopharmacology (Berl) 2016 Jan;233(1):99-109       34 Citations
1Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. (Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA) Leukemia 2016 Feb;30(2):346-50       91 Citations
2Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2       31 Citations
1In reply: Observational study of prolonged times to tracheal extubation. (Tabing AK, Ehrenfeld JM, Wanderer JP) Can J Anaesth 2016 Jan;63(1):117-8       1 Citation
1Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. (Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, Liu C, McDonald DG, Pidala J, Yu XZ) PLoS One 2015;10(9):e0137641       81 Citations
1Limiting the accessibility of cost-prohibitive drugs reduces overall anesthetic drug costs: a retrospective before and after analysis. (Tabing AK, Ehrenfeld JM, Wanderer JP) Can J Anaesth 2015 Oct;62(10):1045-54       19 Citations
1Disruption of peri-adolescent endocannabinoid signaling modulates adult neuroendocrine and behavioral responses to stress in male rats. (Lee TT, Hill MN, Hillard CJ, Gorzalka BB) Neuropharmacology 2015 Dec;99:89-97       20 Citations
1Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. (Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA) JAMA Oncol 2015 Apr;1(1):80-7       525 Citations
1Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC) Blood 2015 Aug 13;126(7):842-50       122 Citations
1Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. (Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH) J Pharmacol Exp Ther 2015 Aug;354(2):111-20       43 Citations
1Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. (Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ) Blood 2015 Jul 02;126(1):61-8       164 Citations
1BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons. (Zhong P, Liu Y, Hu Y, Wang T, Zhao YP, Liu QS) J Neurosci 2015 Mar 11;35(10):4469-81       35 Citations
1Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. (Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F) Cancer Res 2015 Feb 01;75(3):594-604       74 Citations
1Non-invasive cardiac output monitoring during sinus surgery. (Gollapudy S, Riess ML) J Anesth 2015 Aug;29(4):639       3 Citations
1miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC) Leukemia 2015 May;29(5):1210-3       18 Citations
1A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. (Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA) Blood 2015 Jan 08;125(2):242-8       124 Citations
1Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. (Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR) J Clin Invest 2014 Nov;124(11):4867-76       167 Citations
1Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. (Zhang Z, Wang W, Zhong P, Liu SJ, Long JZ, Zhao L, Gao HQ, Cravatt BF, Liu QS) Hippocampus 2015 Jan;25(1):16-26       81 Citations
1Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. (Fernández-Suárez D, Celorrio M, Riezu-Boj JI, Ugarte A, Pacheco R, González H, Oyarzabal J, Hillard CJ, Franco R, Aymerich MS) Neurobiol Aging 2014 Nov;35(11):2603-2616       79 Citations
1Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. (Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC) N Engl J Med 2014 Jun 12;370(24):2286-94       1100 Citations
1Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. (Zhong P, Wang W, Pan B, Liu X, Zhang Z, Long JZ, Zhang HT, Cravatt BF, Liu QS) Neuropsychopharmacology 2014 Jun;39(7):1763-76       120 Citations
3Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. (Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ) Pharmacol Biochem Behav 2014 Feb;117:17-24       46 Citations
3Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. (Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA) PLoS One 2013;8(8):e70575       62 Citations
1Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC) Blood 2013 Oct 10;122(15):2539-49       703 Citations
1Systemics to topicals in psoriasis: the unfilled need. (Lingam P, Nwe S, Gordon KB) Br J Dermatol 2013 Jul;169(1):2-3    
1NR2A- and NR2B-containing NMDA receptors in the prelimbic medial prefrontal cortex differentially mediate trace, delay, and contextual fear conditioning. (Gilmartin MR, Kwapis JL, Helmstetter FJ) Learn Mem 2013 May 15;20(6):290-4       59 Citations
1Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. (Starenki D, Park JI) J Clin Endocrinol Metab 2013 Apr;98(4):1529-40       44 Citations
1Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. (Kizhakekuttu TJ, Wang J, Dharmashankar K, Ying R, Gutterman DD, Vita JA, Widlansky ME) Arterioscler Thromb Vasc Biol 2012 Oct;32(10):2531-9       90 Citations
2Pontine μ-opioid receptors mediate bradypnea caused by intravenous remifentanil infusions at clinically relevant concentrations in dogs. (Prkic I, Mustapic S, Radocaj T, Stucke AG, Stuth EA, Hopp FA, Dean C, Zuperku EJ) J Neurophysiol 2012 Nov;108(9):2430-41       72 Citations
1Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. (Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, Huang XP, Trapella C, Guerrini R, Calo G, Roth BL, Cherezov V, Stevens RC) Nature 2012 May 16;485(7398):395-9       425 Citations
1Hemoglobin desaturation after propofol/remifentanil-induced apnea: a study of the recovery of spontaneous ventilation in healthy volunteers. (Stefanutto TB, Feiner J, Krombach J, Brown R, Caldwell JE) Anesth Analg 2012 May;114(5):980-6       19 Citations
2Structure of the human κ-opioid receptor in complex with JDTic. (Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, Mascarella SW, Westkaemper RB, Mosier PD, Roth BL, Cherezov V, Stevens RC) Nature 2012 Mar 21;485(7398):327-32       793 Citations
1Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. (McLaughlin RJ, Hill MN, Bambico FR, Stuhr KL, Gobbi G, Hillard CJ, Gorzalka BB) Eur Neuropsychopharmacol 2012 Sep;22(9):664-71       99 Citations
3Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. (Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, Franczak MB, Goveas JS, Li SJ) Neuroimage 2012 Apr 02;60(2):1083-91       102 Citations
2Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. (Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB) Endocrinology 2012 Jan;153(1):29-41       34 Citations
1Activity dependent protein degradation is critical for the formation and stability of fear memory in the amygdala. (Jarome TJ, Werner CT, Kwapis JL, Helmstetter FJ) PLoS One 2011;6(9):e24349       164 Citations
2Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. (Vaughn LK, Mantsch JR, Vranjkovic O, Stroh G, Lacourt M, Kreutter M, Hillard CJ) Neuroscience 2012 Mar 01;204:117-24       38 Citations
1Extracellular signal-regulated kinase signaling in the ventral tegmental area mediates cocaine-induced synaptic plasticity and rewarding effects. (Pan B, Zhong P, Sun D, Liu QS) J Neurosci 2011 Aug 03;31(31):11244-55       58 Citations
3Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. (Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT, Karatsoreos IN, Mackie K, Viau V, Pickel VM, McEwen BS, Liu QS, Gorzalka BB, Hillard CJ) J Neurosci 2011 Jul 20;31(29):10506-15       309 Citations
3Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. (Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M, Jones JL, Antuono PG, Li SJ) J Magn Reson Imaging 2011 Oct;34(4):764-73       87 Citations
1Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. (Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC) Blood 2011 Jun 09;117(23):6287-96       711 Citations
1Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone. (Hwang JY, Huang W, Arnold LA, Huang R, Attia RR, Connelly M, Wichterman J, Zhu F, Augustinaite I, Austin CP, Inglese J, Johnson RL, Guy RK) J Biol Chem 2011 Apr 08;286(14):11895-908       33 Citations
1Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. (Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu QS, Lichtman AH, Cravatt BF) Nat Neurosci 2010 Sep;13(9):1113-9       555 Citations
3Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. (Ho WS, Patel S, Thompson JR, Roberts CJ, Stuhr KL, Hillard CJ) Br J Pharmacol 2010 Jun;160(3):736-46       10 Citations
1Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. (Ludwig K, Viscusi ER, Wolff BG, Delaney CP, Senagore A, Techner L) World J Surg 2010 Sep;34(9):2185-90       38 Citations
1Endogenous cannabinoid signaling is essential for stress adaptation. (Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V) Proc Natl Acad Sci U S A 2010 May 18;107(20):9406-11       305 Citations
1IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. (Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P) Proc Natl Acad Sci U S A 2010 Mar 02;107(9):4448-53       301 Citations
1The effects of desflurane and sevoflurane on hepatic and renal functions after right hepatectomy in living donors*. (Ko JS, Gwak MS, Choi SJ, Yang M, Kim MJ, Lee JY, Kim GS, Kwon CH, Joh JW) Transpl Int 2010 Jul;23(7):736-44       33 Citations
2Clinically relevant infusion rates of mu-opioid agonist remifentanil cause bradypnea in decerebrate dogs but not via direct effects in the pre-Bötzinger complex region. (Mustapic S, Radocaj T, Sanchez A, Dogas Z, Stucke AG, Hopp FA, Stuth EA, Zuperku EJ) J Neurophysiol 2010 Jan;103(1):409-18       55 Citations
1Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. (Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB) Neuropsychopharmacology 2009 Dec;34(13):2733-45       263 Citations
1Partial attenuation of cytotoxicity and apoptosis by SOD1 in ischemic renal epithelial cells. (Liang HL, Arsenault J, Mortensen J, Park F, Johnson CP, Nilakantan V) Apoptosis 2009 Oct;14(10):1176-89       21 Citations
2Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. (Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, Liu QS) J Pharmacol Exp Ther 2009 Nov;331(2):591-7       143 Citations
2D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. (Pan B, Hillard CJ, Liu QS) J Neurosci 2008 Dec 24;28(52):14018-30       114 Citations
1Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. (Ludwig K, Enker WE, Delaney CP, Wolff BG, Du W, Fort JG, Cherubini M, Cucinotta J, Techner L) Arch Surg 2008 Nov;143(11):1098-105       132 Citations
1Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. (Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, Malan TP Jr, Yamamura HI, Ossipov MH, King T, Lai J, Porreca F, Vanderah TW) J Neurosci 2008 Nov 05;28(45):11593-602       80 Citations
1The effects of desflurane and propofol-remifentanil on postoperative hepatic and renal functions after right hepatectomy in liver donors. (Ko JS, Gwak MS, Choi SJ, Kim GS, Kim JA, Yang M, Lee SM, Cho HS, Chung IS, Kim MH) Liver Transpl 2008 Aug;14(8):1150-8       37 Citations
1The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. (Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H, LEADe investigators) Alzheimers Dement 2008 Mar;4(2):145-53       61 Citations
2Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. (Hillard CJ, Ho WS, Thompson J, Gauthier KM, Wheelock CE, Huang H, Hammock BD) Br J Pharmacol 2007 Nov;152(5):691-8       29 Citations
1Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway. (O'Connor PM, Cowley AW Jr) Am J Physiol Renal Physiol 2007 Aug;293(2):F526-32       24 Citations
1Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. (Wolff BG, Weese JL, Ludwig KA, Delaney CP, Stamos MJ, Michelassi F, Du W, Techner L) J Am Coll Surg 2007 Apr;204(4):609-16       58 Citations
1Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. (Rademacher DJ, Hillard CJ) Prog Neuropsychopharmacol Biol Psychiatry 2007 Apr 13;31(3):633-41       72 Citations
1Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. (Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB) Neuropsychopharmacology 2006 Dec;31(12):2591-9       109 Citations
2Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. (Carrier EJ, Auchampach JA, Hillard CJ) Proc Natl Acad Sci U S A 2006 May 16;103(20):7895-900       415 Citations
1Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. (Patel S, Roelke CT, Rademacher DJ, Hillard CJ) Eur J Neurosci 2005 Feb;21(4):1057-69       265 Citations
1Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. (Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ) Neuroscience 2004;129(3):743-50       131 Citations
1Immunomodulatory and antitumor activity of Piper longum Linn. and piperine. (Sunila ES, Kuttan G) J Ethnopharmacol 2004 Feb;90(2-3):339-46       447 Citations
1Sympathetic and vascular consequences from remifentanil in humans. (Noseir RK, Ficke DJ, Kundu A, Arain SR, Ebert TJ) Anesth Analg 2003 Jun;96(6):1645-1650       65 Citations
1Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. (Rademacher DJ, Patel S, Hopp FA, Dean C, Hillard CJ, Seagard JL) Am J Physiol Heart Circ Physiol 2003 May;284(5):H1570-6       32 Citations
2The CB1 receptor antagonist SR141716 enhances stimulus-induced activation of the primary somatosensory cortex of the rat. (Patel S, Gerrits R, Muthian S, Greene AS, Hillard CJ) Neurosci Lett 2002 Dec 25;335(2):95-8       15 Citations
1Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. (Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G) Cancer Chemother Pharmacol 2002 Dec;50(6):465-72       119 Citations
1Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. (Patel S, Hillard CJ) J Pharmacol Exp Ther 2001 May;297(2):629-37       79 Citations
1Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. (Tyler K, Hillard CJ, Greenwood-Van Meerveld B) Eur J Pharmacol 2000 Dec 08;409(2):207-11       57 Citations
1Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. () Lancet 2000 Jan 29;355(9201):337-45       277 Citations
1Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2). (Alexanian AR, Arutyunian NS) Invest New Drugs 1999;17(2):105-10       3 Citations
1Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. (Hillard CJ, Muthian S, Kearn CS) FEBS Lett 1999 Oct 08;459(2):277-81       94 Citations
1Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. (Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ) J Neurochem 1999 Jun;72(6):2379-87       109 Citations
1Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. (Schultz JE, Kwok WM, Hsu AK, Gross GJ) J Mol Cell Cardiol 1998 Sep;30(9):1817-25       7 Citations
2N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. (Pratt PF, Hillard CJ, Edgemond WS, Campbell WB) Am J Physiol 1998 Jan;274(1):H375-81       110 Citations
1Interactions between neuronal histamine and halothane anesthesia in rats. (Mammoto T, Yamamoto Y, Kagawa K, Hayashi Y, Mashimo T, Yoshiya I, Yamatodani A) J Neurochem 1997 Jul;69(1):406-11       18 Citations
1Inhibition of M3 muscarinic acetylcholine receptor-mediated Ca2+ influx and intracellular Ca2+ mobilization in neuroblastoma cells by the Ca2+/calmodulin-dependent protein kinase inhibitor 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-trosyl]-4-phenylpiperazin e (KN-62). (Puhl HL, Raman PS, Williams CL, Aronstam RS) Biochem Pharmacol 1997 Apr 25;53(8):1107-14       10 Citations
1Antiarrhythmic action of the new calcium antagonist [1,2,5-trimethyl-4-phenyl-4-beta-(N-cyanoethyl-N-4'-methoxybenzyl) -ethylamino]piperidine dihydrochloride. (Alexanian AR, Arutyunian NS, Galoyan AA) Arzneimittelforschung 1996 Dec;46(12):1110-3       3 Citations
1Delayed rectification in single cells isolated from guinea pig sinoatrial node. (Anumonwo JM, Freeman LC, Kwok WM, Kass RS) Am J Physiol 1992 Mar;262(3 Pt 2):H921-5       63 Citations
1Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. (Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, Willerson JT) Circulation 1986 Mar;73(3):572-8    
1The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. (Bush LR, Campbell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT) Circ Res 1984 Nov;55(5):642-52    
1Adrenergic component of renin release induced by vasodilating antihypertensive drugs in the rat. (Pettinger WA, Campbell WB, Keeton K) Circ Res 1973 Jul;33(1):82-6       91 Citations